Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients.

作者信息

Ix Joachim H, Ganjoo Prerna, Tipping Diane, Tershakovec Andrew M, Bostom Andrew G

出版信息

Am J Kidney Dis. 2011 Jun;57(6):963-5. doi: 10.1053/j.ajkd.2011.03.010. Epub 2011 Apr 15.

DOI:10.1053/j.ajkd.2011.03.010

PMID:21496982

Abstract

摘要

相似文献

[1]

Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients.

Am J Kidney Dis. 2011-6

[2]

Safety of extended-release niacin/laropiprant in patients with dyslipidemia.

J Clin Lipidol. 2010-2-12

[3]

Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.

Int J Clin Pract. 2010-5

[4]

Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.

Clin J Am Soc Nephrol. 2010-3-18

[5]

Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.

J Clin Lipidol. 2010-10-28

[6]

Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.

Expert Opin Pharmacother. 2012-6

[7]

Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes.

J Clin Lipidol. 2011-5-13

[8]

Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.

Cardiol Clin. 2008-11

[9]

Safety and tolerability of extended-release niacin with laropiprant.

Expert Opin Drug Saf. 2011-12-1

[10]

Dyslipidaemia: Failure to THRIVE: the end for niacin?

Nat Rev Cardiol. 2013-5

引用本文的文献

[1]

Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.

J Am Soc Nephrol. 2019-5-13

[2]

The effect of chronic kidney disease on lipid metabolism.

Int Urol Nephrol. 2019-2

[3]

More than skin deep? Potential nicotinamide treatment applications in chronic kidney transplant recipients.

World J Transplant. 2016-12-24

[4]

Nicotinamide and phosphate homeostasis in chronic kidney disease.

Curr Opin Nephrol Hypertens. 2016-7

[5]

Phosphate and FGF-23 homeostasis after kidney transplantation.

Nat Rev Nephrol. 2015-9-29

[6]

Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease.

Curr Opin Nephrol Hypertens. 2015-5

[7]

Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.

J Am Soc Nephrol. 2015-10

[8]

Effect of niacin on FGF23 concentration in chronic kidney disease.

Am J Nephrol. 2014

[9]

Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Nat Rev Nephrol. 2014-4-1

[10]

Phosphate control in end-stage renal disease: barriers and opportunities.

Nephrol Dial Transplant. 2013-7-30

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

引用本文的文献